在实验性心力衰竭中最大化 natriuretic 系统:皮下大脑 natriuretic 和急性血管酶抑制
Horng H Chen1, John G Lainchbury, Gail J Harty
1Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Department of Physiology, Mayo Clinic and Foundation, Rochester, Minn 55905, USA. chen.horng@mayo.edu
Circulation
|February 28, 2002
概括
急性血管胺酶抑制剂 (VPI) 的使用在实验性充血性心力衰竭 (CHF) 中增强了脑内尿性 (BNP) 的作用. 将VPI与BNP结合起来,提供了一种新的治疗策略,以增强CHF患者的心脏和脏功能.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 充血性心力衰竭 (CHF) 的特点是心脏 natriuretic (NP) 的升高,具有有益的心脏和鼻性质.
- 慢性皮下 (SQ) 大脑 natriuretic (BNP) 管理改善心脏功能在实验性CHF.
- 血管酶抑制剂 (VPIs) 同时抑制中性内酶 (NEP) 和ACE.
研究的目的:
- 调查急性VPI给药是否增强SQ BNP在实验性CHF中的心脏脏作用.
- 评估VPI和BNP对心脏和脏和幽默反应的综合影响.
主要方法:
- 研究了经过麻醉的狗,其心室节奏诱导的CHF被研究.
- 这些组仅接受急性VPI,低剂量SQ BNP,高剂量SQ BNP,或VPI加低剂量SQ BNP.
- 测量了心脏和幽默的参数.
主要成果:
- 与VPI或低剂量BNP单独相比,VPI加上低剂量SQ BNP显著增加了血BNP水平.
- 联合VPI和BNP的使用导致尿路BNP和分泌量最高.
- 组合疗法导致了最大的膜过率,心脏输出率的增加和心脏填充压力的降低.
结论:
- 急性VPI的使用可增强SQ BNP在实验性CHF中的心脏和脏效应.
- 将蛋白质疗法与BNP和血管抑制相结合,为心血管衰竭治疗提供了一种新的策略.
- 这种方法最大限度地提高了 natriuretic 系统在治疗CHF 的治疗效益.
相关概念视频
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
01:22Heart Failure Drugs: Diuretics
1.8K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:22Heart Failure Drugs: β-Blockers
2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K
01:29Heart Failure II: Pathophysiology
2.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.1K
01:30Heart Failure V: Medical Management
641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641